Synopsys Forecast, price target & analysts
Synopsys Target price 2025 - Analyst rating & recommendation
Synopsys Classifications & Recommendation:
Synopsys Price Target
| Target Price | $637.50 |
| Price | $606.52 |
| Potential | 5.11% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Synopsys 2026 . The average Synopsys target price is $637.50. This is 5.11% higher than the current stock price. The highest price target is $735.00 21.18% , the lowest is $525.20 13.41% . | |
| A rating was issued by 28 analysts: 25 Analysts recommend Synopsys to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2026 of 5.11% . Most analysts recommend the Synopsys stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2028
26 Analysts have issued a sales forecast Synopsys 2025 . The average Synopsys sales estimate is $7.0b . This is 13.21% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $7.9b 27.43% , the lowest is $6.6b 5.77% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $6.1b | 15.22% |
|---|---|---|
| 2025 | $7.0b | 14.94% |
| 2026 | $8.4b | 18.70% |
| 2027 | $9.5b | 14.08% |
| 2028 | $12.8b | 34.52% |
18 Analysts have issued an Synopsys EBITDA forecast 2025. The average Synopsys EBITDA estimate is $2.9b . This is 123.88% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.2b 145.93% , the lowest is $2.8b 109.51% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $1.4b | 2.72% |
|---|---|---|
| 2025 | $2.9b | 114.66% |
| 2026 | $3.6b | 20.65% |
| 2027 | $4.1b | 16.72% |
EBITDA Margin
| 2024 | 22.39% | 10.85% |
|---|---|---|
| 2025 | 41.81% | 86.73% |
| 2026 | 42.50% | 1.65% |
| 2027 | 43.48% | 2.31% |
26 Synopsys Analysts have issued a net profit forecast 2025. The average Synopsys net profit estimate is $2.4b . This is 9.82% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 14.09% , the lowest is $2.1b 3.70% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $2.3b | 84.03% |
|---|---|---|
| 2025 | $2.4b | 4.96% |
| 2026 | $2.6b | 11.36% |
| 2027 | $3.1b | 17.86% |
| 2028 | $3.9b | 26.02% |
Net Margin
| 2024 | 36.94% | 59.72% |
|---|---|---|
| 2025 | 33.73% | 8.69% |
| 2026 | 31.64% | 6.20% |
| 2027 | 32.69% | 3.32% |
| 2028 | 30.63% | 6.30% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
26 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is $15.31 . This is 10.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.91 14.87% , the lowest is $13.43 3.03% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $14.51 | 83.21% |
|---|---|---|
| 2025 | $15.31 | 5.51% |
| 2026 | $17.05 | 11.37% |
| 2027 | $20.10 | 17.89% |
| 2028 | $25.33 | 26.02% |
P/E ratio
| Current | 43.79 | 23.50% |
|---|---|---|
| 2025 | 39.61 | 9.55% |
| 2026 | 35.57 | 10.20% |
| 2027 | 30.18 | 15.15% |
| 2028 | 23.95 | 20.64% |
Based on analysts' sales estimates for 2025, the Synopsys stock is valued at an EV/Sales of 15.34 and an P/S ratio of 15.94 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 17.36 | 28.40% |
|---|---|---|
| 2025 | 15.34 | 11.65% |
| 2026 | 12.92 | 15.75% |
| 2027 | 11.33 | 12.34% |
| 2028 | 8.42 | 25.66% |
P/S ratio
| Current | 18.04 | 30.28% |
|---|---|---|
| 2025 | 15.94 | 11.67% |
| 2026 | 13.43 | 15.75% |
| 2027 | 11.77 | 12.34% |
| 2028 | 8.75 | 25.66% |
Current Synopsys Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 11 2025 |
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 25 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jul 21 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Jul 16 2025 |
| Needham |
Buy
➜
Buy
|
Unchanged | Jul 15 2025 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 10 2025 |
| Goldman Sachs |
➜
Buy
|
Initiated | Jul 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 11 2025 |
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 25 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jul 21 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jul 16 2025 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Jul 15 2025 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 10 2025 |
|
Initiated
Goldman Sachs:
➜
Buy
|
Jul 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
